Frontier Biotechnologies Inc.

Frontier Biotechnologies Inc.

About

Company description

Frontier Biotechnologies Inc. is a research-based pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing significant unmet medical needs. - Its lead product candidate ALBUVIRTIDE, a novel long-acting anti-HIV agent. - The second lead drug candidate AB001 is a third generation topical patch for the management of pain and inflammation, and a phase 2 clinical trial of AB001 for the treatment of chronic low back pain was successfully completed in the US.  - Frontier Biotechnologies, Inc., announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117, a novel broad-spectrum HIV neutralizing antibody, with ALBUVIRTIDE for the treatment and prophylaxis of HIV infection and AIDS.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Antibodies |Biochemicals |Other APIs More

Upcoming events

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany Visit us at stand 92B35NEP Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

9 oct 2018

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain We were at stand 12B11 See our Exhibitor Profile   See full Exhibitor List
24 oct 2017

CPhI Worldwide 2017

24 - 26 October 2017 Messe Frankfurt, Germany We were at stand 60A01 See our Exhibitor Profile   See full Exhibitor List
Frontier Biotechnologies Inc.

Contact information

Address

Telephone

Website

View all contact information